Perelman School of Medicine, Department of Surgery, University of Pennsylvania, Philadelphia.
JAMA Surg. 2020 Nov 1;155(11):1068-1077. doi: 10.1001/jamasurg.2020.1463.
Patients who have had splenectomy have a lifelong risk of overwhelming postsplenectomy infection (OPSI), a condition associated with high mortality rates. Surgeons must be aware of the rationale of vaccination in the case of splenectomy, to provide appropriate immunization in the perioperative time.
English-language articles published from January 1, 1990, to December 31, 2019, were retrieved from MEDLINE/PubMed, Cochrane Library, and ClinicalTrials.gov databases. Randomized clinical trials as well as systematic reviews and observational studies were considered. Asplenia yields an impairment of both innate and adaptive immunity, thus increasing the risk of severe encapsulated bacterial infections. Current epidemiology of OPSI ranges from 0.1% to 8.5% but is hard to ascertain because of ongoing shifts in patients' baseline conditions and vaccine penetration. Despite the lack of randomized clinical trials, immunization appears to be effective in reducing OPSI incidence. Unfortunately, vaccination coverage is still suboptimal, with a great variability in vaccination rates being reported across institutions and time frames. Notably, current guidelines do not advocate any particular health care qualification responsible for vaccine prescription or administration. Given the dearth of high-level basic science or clinical evidence, the optimal vaccination timing and the need for booster doses are not yet well established. Although almost all guidelines indicate to not administer vaccines within 14 days before and after surgery, most data suggest that immunization might be effective even in the immediate perioperative time, thus placing the surgeon in a primary position for vaccine delivery. Furthermore, revaccination schedules are the target of ongoing debates, since a vaccine-driven hyporesponsiveness has been postulated.
In patients who have undergone splenectomy, OPSI might be effectively prevented by proper immunization. Surgeons have the primary responsibility for achieving adequate, initial immunization in the setting of both planned and urgent splenectomy.
接受脾切除术的患者有终生发生脾切除后全身性感染(OPSI)的风险,这种情况与高死亡率相关。外科医生必须了解脾切除术时疫苗接种的基本原理,以便在围手术期提供适当的免疫接种。
从 MEDLINE/PubMed、Cochrane 图书馆和 ClinicalTrials.gov 数据库中检索了 1990 年 1 月 1 日至 2019 年 12 月 31 日期间发表的英文文章。考虑了随机临床试验以及系统评价和观察性研究。脾切除术后会导致固有免疫和适应性免疫受损,从而增加严重包囊细菌感染的风险。目前 OPSI 的流行病学范围为 0.1%至 8.5%,但由于患者基线状况和疫苗接种率的持续变化,很难确定。尽管缺乏随机临床试验,但免疫接种似乎可有效降低 OPSI 的发病率。不幸的是,疫苗接种覆盖率仍然不理想,不同机构和时间框架报告的疫苗接种率差异很大。值得注意的是,目前的指南不主张任何特定的医疗保健资格负责疫苗处方或管理。鉴于缺乏高级基础科学或临床证据,最佳疫苗接种时机和加强剂量的需求尚未得到充分确立。尽管几乎所有指南都表明在手术前后 14 天内不接种疫苗,但大多数数据表明,即使在围手术期立即进行免疫接种也可能有效,从而使外科医生成为疫苗接种的主要实施者。此外,由于已经假设疫苗接种会导致低反应性,因此重新接种计划成为正在进行的辩论的目标。
在接受脾切除术的患者中,适当的免疫接种可有效预防 OPSI。外科医生有主要责任在计划和紧急脾切除术中实现充分的初始免疫接种。